Company intelligence / Profile preview

Baymatob

Leichhardt, New South Wales, Australiabaymatob.com ↗

Ownership: Private
Employees: ~13
Development stage: Other

Overview

Baymatob has developed the Oli AI-guided wearable maternity sensor to predict risk of postpartum hemorrhage before birth. A pilot study with 500 mothers showed that over 80% of mothers who developed PPH could have been identified for early intervention using the device. The company has received FDA Breakthrough Device Designation and is preparing for pivotal trials to support regulatory submissions.

Therapeutic areas: Women's Health
Modalities: DeviceArtificial intelligence-guided monitoring platform
Industry: Physiological Monitoring

Partnerships

Australian Unity's Future of Healthcare Fund (investment partner)CUREator+ accelerator program funded by Australia’s Medical Research Future Fund

Beyond the preview

Go deeper on Baymatob.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Baymatob.

Explore the full profile